Trial Profile
A Phase 1, Randomized Trial to Assess the Safety, Reactogenicity, and Immunogenicity of a Combination HTNV and PUUV DNA Vaccine Candidate Administered by Electroporation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs PWRG-HTN-M(co)/pWRG-PUUV-M(s2) (Primary) ; PWRG-HTN-M(co)/pWRG-PUUV-M(s2) (Primary)
- Indications Viral haemorrhagic fevers
- Focus Adverse reactions
- 16 May 2022 Planned End Date changed from 1 Dec 2021 to 30 Apr 2023.
- 16 May 2022 Planned primary completion date changed from 1 Dec 2021 to 30 Dec 2022.
- 16 May 2022 Status changed from recruiting to active, no longer recruiting.